

Reviewer 1

1. Median follow up after transplant: 732 days (37-2016)
2. Median interval between PET and transplant: 77 days (7-363)
3. I wish we could, but we can't...
4. Table:

Patient	N lesions	Size (largest lesion)	Vascular invasion	Differentiation	pTNM (7th, 2010)
1	3	2,6	Y	low	T2
2	2	3,2	N	high	T2
3	1	1,5	N	moderate	T1
4	2	3,5	Y	moderate	T2
5	2	4,5	N	high	T2
6	1	2,0	Y	high	T2
7	2	5,0	N	high	T2
8	1	3,0	N	moderate	T1
9	>3	5,0	Y	moderate	T3a
10	>3	2,4	Y	moderate	T3b
11	>3	6,0	N	high	T3a
12	>3	1,9	N	high	T2
13	>3	2,7	N	high	T2
14	>3	2,6	Y	high	T2
15	3	3,5	N	moderate	T2
16	>3	9,0	N	moderate	T3a
17	2	3,0	N	moderate	T2
18	1	3,0	N	high	T1
19	3	4,0	Y	high	T2
20	>3	4,5	N	moderate	T2
21	>3	6,5	Y	moderate	T3a
22	>3	2,5	Y	moderate	T4
23	>3	3,8	N	moderate	T2
24	>3	2,3	N	moderate	T2
25	1	2,2	N	high	T1
26	>3	3,0	Y	high	T2
27	2	11,5	N	high	T3a

5. Nous n'avons pas ces chiffres. S'agit-il de la survie médiane ou de la proportion de récurrence/décès ?


Si on considère la figure 2, il y a 8 sujets avec 1 ratio > 1.15, dont 4 ont récidivé. Sur les 19 sujets avec 1 ratio < 1.15, un seul a récidivé.

6. Pretransplant treatment: Not sure what he means by that. Eight pts received neoadjuvant tt, i.e. embolization or chemoembolization

7. HBV: 8, HCV: 6, both HBC and HCV: 1

8. ROC curve for tumor recurrence:

Courbe ROC pour récidive



AUC=0.836

Reviewer 2:

1. see reviewer 1
2. I leave it to you...
3. I agree
4. Again we don't have these data..should we go back and ask the statisticians ??
5. The AFP and Milan criteria were those at the initial evaluation (I think...)

